CVS Caremark Rx blasted the findings for cherry picking certain drugs in an effort to push what it called an 'anti-PBM' ...

From 2017 to 2022, the companies marked up prices at their pharmacies by hundreds or thousands of percent, netting them $7.3 ...

The Federal Trade Commission voted unanimously to release additional findings from its yearslong probe into CVS Caremark, ...

The Federal Trade Commission on Tuesday released an interim report saying that powerful drug middlemen marked up drugs for ...

The new document focuses on the influence of PBMs over the market for specialty generic drugs for illnesses like cancer, ...

The nation's three largest pharmacy benefit managers have significantly marked up the prices of certain medicines, including ...

Agency commissioners voted unanimously on Tuesday to publish the report, which makes similar allegations against the ...

Pharmacy benefit managers, which serve as the middlemen between drug makers, insurers and pharmacies, reaped $7.3 billion in ...

The FTC study examines the practices of PBMs to ensure fair competition and transparency. The FTC found that from 2017 to 2022, the three big PBMs imposed substantial price markups on 51 specialty ...

Prescription benefit managers have been under growing scrutiny from state and federal regulators who have accused them of ...